The objective of this clinical trial was to explore the safety and efficacy of repertaxin in preventing the delayed graft function (DGF) after kidney transplantation.
Ischemia-Reperfusion Injury in Kidney Transplantation
Drug: reparixin continuous infusion
Drug: Reparixin intermittent infusion
Other: placebo infusion
Copyright 2017 © Dompé farmaceutici S.p.A. All rights reserved.
Dompè does not assume any responsibility for the contents